Evidence map›Paper›PMID 40560499›Full record

ReviewAnnals of surgical oncology2026

Consensus Guideline for the Management of Gastric Cancer with Synchronous Peritoneal Metastases.

Samuel D Butensky, Varun V Bansal, David G Su, Muhammad Talha Waheed, Andrei Nikiforchin, Jorge L Gomez-Mayorga, Elizabeth Olecki, Shannon N Radomski, Beatrice Sun, Kiran K Turaga and 10 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Samuel D ButenskyYale School of Medicine, Yale University, New Haven, CT, USA.
Varun V BansalYale School of Medicine, Yale University, New Haven, CT, USA.
David G SuYale School of Medicine, Yale University, New Haven, CT, USA.
Muhammad Talha WaheedCity of Hope National Medical Center, Duarte, CA, USA.
Andrei NikiforchinMercy Medical Center, Baltimore, MD, USA.
Jorge L Gomez-MayorgaBeth Israel Deaconess Medical Center, Boston, MA, USA.
Elizabeth OleckiThe Pennsylvania State University, Hershey, PA, USA.
Shannon N RadomskiJohns Hopkins University, Baltimore, MD, USA.
Beatrice SunStanford University, Stanford, CA, USA.
Kiran K TuragaYale School of Medicine, Yale University, New Haven, CT, USA. kiran.turaga@yale.edu.
Craig G GundersonYale School of Medicine, Yale University, New Haven, CT, USA.
Jill LacyYale School of Medicine, Yale University, New Haven, CT, USA.
Brian D BadgwellMD Anderson Cancer Center, Houston, TX, USA.
Haejin InRutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Timothy KennedyRutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Harry H YoonMayo Clinic, Rochester, MN, USA.
Jonathan B GreerMassachusetts General Hospital, Boston, MA, USA.
Raghav SundarYong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Yanghee WooCity of Hope National Medical Center, Duarte, CA, USA.
Peritoneal Surface Malignancies (PSM) Consortium Group

Funding

Yale Cancer Center Advanced Training Program for Physician-Scientists (YCC-ATPP)T32CA233414 · NCI · YALE UNIVERSITY · PI Eric P. Winer · 2019 to 2026
$3.2M
NCI NIH HHS T32 CA233414
6 · The paper itself

Abstract

backgroundGastric cancer with synchronous peritoneal metastases (GCPM) is a debilitating disease with limited treatment options. This manuscript describes an update of the 2018 Chicago Consensus Guidelines addressing the management of GCPM in line with most recent evidence.

methodsA clinical management pathway was updated through two rounds of a Delphi Consensus to assess agreement levels with pathway blocks. Supporting evidence underwent evaluation via a rapid literature review. Meta-analyses were performed where appropriate.

resultsOverall, level of evidence in this disease subset was low to moderate. Of 124 participants in the first round, 109 (88%) responded in the second round. Strong consensus (>90%) was achieved in 6/8 (75%) blocks in round I and II. A multidisciplinary preoperative assessment and diagnostic laparoscopy should be offered to all patients, while patients with a high burden of disease or progression should undergo non-surgical management. Patients with stable/responsive disease and low peritoneal carcinomatosis index should subsequently be offered treatment with regional therapeutic interventions and cytoreductive surgery. In patients who are cytology positive, systemic therapy can be used to convert these patients to cytology negative, with subsequent surgery offered per the patient's goals of care. Meta-analysis of observational and randomized control trials revealed a survival benefit with the addition of intraperitoneal chemotherapy to cytoreductive surgery (HR 0.52).

conclusionThe consensus-driven clinical pathway for GCPMs offers vital clinical guidance for practitioners. There is a growing body of high-quality evidence to support management strategies and future clinical trials are eagerly awaited.

Indexed as

Peritoneal NeoplasmsPractice Guidelines as TopicStomach NeoplasmsConsensusCytoreduction Surgical ProceduresHumansPrognosisCytoreductive surgical proceduresGastric cancerGuidelinesPeritoneal surface malignanciesPeritoneal surface neoplasms

Identifiers

PMID40560499

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.